HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. The company is headquartered in Boston, Massachusetts and currently employs 14 full-time employees. The firm's programs, HIL-214 and HIL-216, are virus-like particle (VLP) based vaccine candidates in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. HIL-214 consists of VLPs which are designed to mimic the structure of norovirus and are co-formulated with an alum adjuvant to enhance immunogenicity and stability of the VLPs in solution. HIL-214 is administered intramuscularly via prefilled syringes and has demonstrated stability at standard refrigeration temperatures of four degrees Celsius for 24 months. The firm has in-licensed HIL-216 from Chengdu Kanghua Biological Products Co., Ltd. (Kangh), a Chinese company. Its license provides world-wide rights to the vaccine outside of the Chinese market. HIL-216 includes six common norovirus genotypes: GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.
Rheon Automatic Machinery Co., Ltd. 주요 수익원은 Food Processing Machinery Manufacturing이며, 최신 수익 발표에서 수익은 23,028,084,000입니다. 지역별로는 North America and South America이 Rheon Automatic Machinery Co., Ltd.의 주요 시장이며, 수익은 20,514,859,000입니다.
Hillevax Inc은 수익성이 있나요?
no, 최신 재무제표에 따르면 Rheon Automatic Machinery Co., Ltd.의 순손실은 $0입니다.
Hillevax Inc에 부채가 있나요?
no, Rheon Automatic Machinery Co., Ltd.의 부채는 0입니다.
Hillevax Inc의 발행 주식은 몇 주인가요?
Rheon Automatic Machinery Co., Ltd.의 총 발행 주식은 0주입니다.